The benefit-risk balance is tipping more in favor of Eli Lilly’s Kisunla in early Alzheimer’s disease as the FDA approves a ...

The newly recommended dosing schedule significantly lowered ARIA-E rates compared to the original dosing schedule, adding to the established safety profile of the treatment "We are confident that this ...

Eli Lilly has won a green light from the FDA for new dosing for its Alzheimer's disease therapy Kisunla, which carries a ...

The FDA will allow a new dosing schedule for Eli Lilly’s Alzheimer’s drug Kisunla that could lessen a known side effect of ...

The U.S. Food and Drug Administration approved changing the prescribing information for Eli Lilly's Alzheimer's drug Kisunla to allow more gradual dosing to lower the risk of a potentially dangerous ...

Kisunla is a newer treatment that works to slow down how fast Alzheimer’s progresses. It contains an antibody called donanemab-azbt, which targets and clears amyloid from the brain.

Kisunla (donanemab-azbt) is a prescription drug that’s used to treat Alzheimer’s disease in adults. Kisunla is given as an intravenous (IV) infusion by a doctor or other healthcare professional.

Kisunla is a prescription drug used to treat Alzheimer's disease. Find out whether it interacts with other drugs, alcohol, supplements, and more.

Both Kisunla and the other approved drug, Leqembi, have been shown to slow down the mental decline of Alzheimer's by more than 25%. But that's in a group of patients—an individual may do much ...

Kisunla applies mostly to those in the mild dementia stage or earlier. READ MORE:Learn more about Kisunla on their website. The center’s President and CEO Dr. Jacylnn Faffer said regardless of ...

Kisunla is currently undergoing a health technology assessment. Two newly approved Alzheimer’s treatments, Kisunla (donanemab ...

The newly recommended dosing schedule significantly lowered ARIA-E rates compared to the original dosing schedule, adding to the established safety profile of the treatment INDIANAPOLIS, ...